<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="wps21073" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">World Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">World Psychiatry</journal-id><journal-id journal-id-type="pmc-domain-id">297</journal-id><journal-id journal-id-type="pmc-domain">worldpsych</journal-id><journal-id journal-id-type="publisher-id">WPS</journal-id><journal-title-group><journal-title>World Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">1723-8617</issn><issn pub-type="epub">2051-5545</issn><publisher><publisher-name>World Psychiatric Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10168177</article-id><article-id pub-id-type="pmcid-ver">PMC10168177.1</article-id><article-id pub-id-type="pmcaid">10168177</article-id><article-id pub-id-type="pmcaiid">10168177</article-id><article-id pub-id-type="pmid">37159360</article-id><article-id pub-id-type="doi">10.1002/wps.21073</article-id><article-id pub-id-type="publisher-id">WPS21073</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Special Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Special Articles</subject></subj-group></article-categories><title-group><article-title>Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention</article-title><alt-title alt-title-type="right-running-head">Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention</alt-title></title-group><contrib-group><contrib id="wps21073-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Volkow</surname><given-names initials="ND">Nora D.</given-names></name><xref rid="wps21073-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>vdrajendra@wiley.com</email></address></contrib><contrib id="wps21073-cr-0002" contrib-type="author"><name name-style="western"><surname>Blanco</surname><given-names initials="C">Carlos</given-names></name><xref rid="wps21073-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="wps21073-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>US National Institute on Drug Abuse</institution>
<city>Bethesda</city>
<named-content content-type="country-part">MD</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>Corresponding author: <email>vdrajendra@wiley.com</email></corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2023</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2023</year></pub-date><volume>22</volume><issue seq="40">2</issue><issue-id pub-id-type="pmc-issue-id">435376</issue-id><issue-id pub-id-type="doi">10.1002/wps.v22.2</issue-id><fpage>203</fpage><lpage>229</lpage><pub-history><event event-type="pmc-release"><date><day>09</day><month>05</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>10</day><month>05</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-05-10 10:25:11.683"><day>10</day><month>05</month><year>2023</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2023 World Psychiatric Association.</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="WPS-22-203.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:WPS-22-203.pdf"/><abstract><p>Substance use disorders (SUDs) are highly prevalent and exact a large toll on individuals&#8217; health, well&#8208;being, and social functioning. Long&#8208;lasting changes in brain networks involved in reward, executive function, stress reactivity, mood, and self&#8208;awareness underlie the intense drive to consume substances and the inability to control this urge in a person who suffers from addiction (moderate or severe SUD). Biological (including genetics and developmental life&#160;stages) and social (including adverse childhood experiences) determinants of health are recognized factors that contribute to vulnerability for or resilience&#160;against developing a SUD. Consequently, prevention strategies that target social risk factors can improve outcomes and, when deployed in childhood and adolescence, can decrease the risk for these disorders. SUDs are treatable, and evidence of clinically significant benefit exists for medications (in opioid, nicotine and alcohol use disorders), behavioral therapies (in all SUDs), and neuromodulation (in nicotine use disorder). Treatment of SUDs should be considered within the context of a Chronic Care Model, with the intensity of intervention adjusted to the severity of the disorder and with the concomitant treatment of comorbid psychiatric and physical conditions. Involvement of health care providers in detection and management of SUDs, including referral of severe cases to specialized care, offers sustainable models of care that can be further expanded with the use of telehealth. Despite advances in our understanding and management of SUDs, individuals with these conditions continue to be stigmatized and, in some countries, incarcerated, highlighting the need to dismantle policies that perpetuate their criminalization and instead develop policies to ensure support and access to prevention and treatment.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="wps21073-kwd-0001">Substance use disorders</kwd><kwd id="wps21073-kwd-0002">addiction</kwd><kwd id="wps21073-kwd-0003">brain networks</kwd><kwd id="wps21073-kwd-0004">social determinants of health</kwd><kwd id="wps21073-kwd-0005">risk factors</kwd><kwd id="wps21073-kwd-0006">prevention</kwd><kwd id="wps21073-kwd-0007">treatment</kwd><kwd id="wps21073-kwd-0008">chronic care model</kwd><kwd id="wps21073-kwd-0009">stigma</kwd></kwd-group><counts><fig-count count="0"/><table-count count="6"/><page-count count="27"/><word-count count="24340"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2023</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.8 mode:remove_FC converted:09.05.2023</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>